Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
iVIZIA is a specialized eye care brand developed through a strategic partnership between Théa Pharma US and Similasan. The company provides a range of over-the-counter (OTC) ophthalmic products designed to treat dry eye syndrome and maintain eyelid hygiene. Its flagship products feature preservative-free formulations incorporating ingredients like hyaluronic acid and trehalose to support the tear film. iVIZIA's portfolio includes lubricant eye drops, eyelid cleansing wipes, and hygiene gels, leveraging Théa's extensive European heritage in ophthalmology. The brand is positioned to address the growing prevalence of ocular surface diseases in the North American market. By combining Similasan's retail expertise with Théa's scientific innovation, iVIZIA offers professional-grade solutions directly to consumers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on iVIZIA.